You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CASE REPORT article

Front. Med.

Sec. Dermatology

Case Report: PTCH1 splice-site mutation and sonidegib treatment in Gorlin-Goltz syndrome: clinical insights from a family case study

  • Suining Central Hospital, Suining, China

Article metrics

View details

68

Views

The final, formatted version of the article will be published soon.

Abstract

Gorlin-Goltz syndrome (nevoid basal cell carcinoma syndrome) is a rare autosomal dominant tumor-predisposition disorder characterized by multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, and variable systemic manifestations. Although pathogenic variants in PTCH1 are a major genetic cause, transcript-level functional evidence for splice-site variants and real-world data on tolerability-oriented dosing of Hedgehog pathway inhibitors remain limited. We report a three-generation family in which a heterozygous canonical PTCH1 splice-donor variant (NM_000264.5:c.3449+1G>A) segregated with disease. A minigene splicing assay demonstrated exon 20 skipping, supporting a loss-of-function mechanism. Two affected relatives with symptomatic BCC burden received oral sonidegib for 6 months using different schedules (200 mg once daily vs 200 mg every other day). Both patients showed clinical regression of target BCC lesions. Dysgeusia and alopecia occurred with daily dosing, whereas every-other-day dosing was well tolerated. This case highlights the value of transcript-level functional assays for interpreting PTCH1 splice-site variants and supports individualized, toxicity-guided sonidegib scheduling in selected patients with Gorlin-Goltz syndrome.

Summary

Keywords

basal cell carcinoma, Gorlin–Goltz syndrome, Hedgehog pathway inhibitor, minigene assay, Ptch1, Sonidegib, splice-site variant

Received

31 December 2025

Accepted

09 February 2026

Copyright

© 2026 LIU, Du, Wang, Lv, Yu and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lingli Deng

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics